Cutaneous adverse events associated with vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma: an observational study of 30 treated patients and presentation of a management algorithm

被引：0
作者：
Sinha, R. [1 ]
Edmonds, K. [2 ]
Newton-Bishop, J. A. [3 ]
Gore, M. [2 ]
Larkin, J. [2 ]
Fearfield, L. A. [1 ]
机构：
[1] Chelsea & Westminster Hosp, London, England
[2] Royal Marsden Hosp, London SW3 6JJ, England
[3] Univ Leeds, Leeds, W Yorkshire, England
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2012年 / 167卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：9 / 10
页数：2
相关论文
共 50 条
  • [41] Safety and Efficacy of Vemurafenib in Patients with BRAFV600 Mutation-Positive Metastatic Melanoma Previously Treated with Ipilimumab: a Subgroup Analysis from a Vemurafenib Expanded Access Program
    Hamid, O.
    Flaherty, L.
    Day, B. -M
    Abhyankar, S.
    Hainsworth, J.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 : 54 - 55
  • [42] Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib
    Lewis, Karl
    Hauschild, Axel
    Larkin, James
    Ribas, Antoni
    Flaherty, Keith T.
    McArthur, Grant A.
    Dreno, Brigitte
    McKenna, Edward
    Zhu, Qian
    Mun, Yong
    Ascierto, Paolo A.
    EUROPEAN JOURNAL OF CANCER, 2019, 116 : 45 - 55
  • [43] Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China
    Gao, Tianfu
    Liu, Jia
    Wu, Jing
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (12)
  • [44] Elucidating value: the role of cost-effectiveness analysis in the decision-making process for the management of BRAF V600E/K mutation-positive melanoma
    Petrou, P.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (12) : 1241 - 1242
  • [45] Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada
    Thomas E. Delea
    Jordan Amdahl
    Alice Wang
    Mayur M. Amonkar
    Marroon Thabane
    PharmacoEconomics, 2015, 33 : 367 - 380
  • [46] Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada
    Delea, Thomas E.
    Amdahl, Jordan
    Wang, Alice
    Amonkar, Mayur M.
    Thabane, Marroon
    PHARMACOECONOMICS, 2015, 33 (04) : 367 - 380
  • [47] Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma
    Tetzlaff, Michael T.
    Pattanaprichakul, Penvadee
    Wargo, Jennifer
    Fox, Patricia S.
    Patel, Keyur P.
    Estrella, Jeannelyn S.
    Broaddus, Russell R.
    Williams, Michelle D.
    Davies, Michael A.
    Routbort, Mark J.
    Lazar, Alexander J.
    Woodman, Scott E.
    Hwu, Wen-Jen
    Gershenwald, Jeffrey E.
    Prieto, Victor G.
    Torres-Cabala, Carlos A.
    Curry, Jonathan L.
    HUMAN PATHOLOGY, 2015, 46 (08) : 1101 - 1110
  • [48] Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1
    Liu, Hui
    Li, Zhongwu
    Wang, Yan
    Feng, Qin
    Si, Lu
    Cui, Chuanliang
    Guo, Jun
    Xue, Weicheng
    PATHOLOGY INTERNATIONAL, 2014, 64 (12) : 601 - 606
  • [49] Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
    Chapman, P. B.
    Robert, C.
    Larkin, J.
    Haanen, J. B.
    Ribas, A.
    Hogg, D.
    Hamid, O.
    Ascierto, P. A.
    Testori, A.
    Lorigan, P. C.
    Dummer, R.
    Sosman, J. A.
    Flaherty, K. T.
    Chang, I.
    Coleman, S.
    Caro, I.
    Hauschild, A.
    McArthur, G. A.
    ANNALS OF ONCOLOGY, 2017, 28 (10) : 2581 - 2587
  • [50] Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
    Si, Lu
    Zhang, Xiaoshi
    Xu, Zhen
    Jiang, Qiudi
    Bu, Lilian
    Wang, Xuan
    Mao, Lili
    Zhang, Weijiang
    Richie, Nicole
    Guo, Jun
    BMC CANCER, 2018, 18
12345